Publication year
2003Source
Urologic Clinics of North America, 30, 3, (2003), pp. 623-31ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Urology
Nuclear Medicine
Journal title
Urologic Clinics of North America
Volume
vol. 30
Issue
iss. 3
Page start
p. 623
Page end
p. 31
Subject
UMCN 1.4: Immunotherapy, gene therapy and transplantationAbstract
Monoclonal antibody G250 treatment may have a role in the management of metastatic RCC; however, particular subgroups who are more prone to benefit from this treatment must be delineated. High-risk patients may benefit from adjuvant treatment with this nontoxic treatment modality. Large cohort studies are needed to investigate this possibility.
This item appears in the following Collection(s)
- Academic publications [227613]
- Faculty of Medical Sciences [86193]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.